Table 3 Treatment-related adverse events at any grade in patients
From: The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
N, grade 1–2, % | N, grade 3, % | |
|---|---|---|
Hand-foot syndrome | 5 (38.5) | 2 (15.4) |
Fatigue | 2 (15.4) | 1 (7.7) |
Mouth ulcers | 4 (30.8) | 1 (7.7) |
Blood toxicities | 5 (38.5) | 1 (7.7) |
Proteinuria | 5 (38.5) | 2 (15.4) |
Diarrhea | 3 (23.1) | 0 (0.0) |
Hypertension | 3 (23.1) | 3 (23.1) |
Elevated creatinine | 1 (7.7) | 0 (0.0) |